A Review on Proniosomes: A Propitious Outlook to the Provesicular Drug
Delivery System

Anamika      Saxena; Pragya      Apurvi; Ramsha      Aslam
Abstract

Currently, various kinds of research are going in the evolution of the Novel Drug Delivery System. NDDS mainly emphasizes the development of a system with improved sustained, controlled, and targeted drug delivery with minimum toxicity. Proniosomes are dry free-flowing formulation that minimizes the drawbacks associated with liposomes and niosomes. Proniosomes are carrier particles that are water-soluble and covered with a surfactant which, upon hydration in a hot aqueous medium with agitation, gives niosomal dispersion. Proniosomes derived niosomes are superior substitutes as compared to other vesicular delivery due to preferable physicochemical properties and improved chemical stability. The proniosomes deliver additional convenience of transportation, storage, distribution, and dosing, which makes dry niosomes a versatile commercial product. This illustrated review emphasizes the components, method of preparation, factors affecting the formation of proniosomes, characterization, and various routes of administration of proniosomes. This review will help to explore the efficacy and functionality of proniosomes in different fields for their upcoming supremacy in the field of drug delivery.
Graphical Abstract

references
[1]
Jain, V.; Jain, S.; Mahajan, S.C. Lipid based vesicular drug delivery system. Adv. Pharm.,  2014, 2014574673
 [http://dx.doi.org/10.1155/2014/574673]

[2]
Sudarshan, U.S.; Rafik, I.N. Proniosomes: A novel vesicular drug delivery system. Am. J. PharmTech Res.,  2020, 10(2), 260-273.
 [http://dx.doi.org/10.46624/ajptr.2020.v10.i2.019]

[3]
Sivaprasad, S.N.V.; Kumar, P.L.; Srinivas, M.; Brahmaiah, B.; Nama, S. Proniosome: A novel approach to vesicular drug delivery system. Int. J. Innov. Drug Discov.,  2013, 3(2), 85-90.

[4]
Sambhakar, S.; Singh, B.; Paliwal, S.; Mishra, P.R. Sorbitol based proniosomes to improve the permeability and stability of an oral cephalo-sporin. Int. J. Drug Deliv.,  2012, 4(2), 236-245.

[5]
Khanam, N.; Alam, M.I.; Sachan, A.K.; Gangwar, S.S.; Sharma, R. Recent trends in drug delivery by niosomes: A review. Asian J. Pharm. Res. Dev.,  2013, 1(3), 115-122.

[6]
Rajesh, M. Review on proniosomes. Int. J. Phar. Pceut. Res.,  2019, 16(3), 345-356.

[7]
Sachan, A.; Kumar, S.; Dwivedi, T. A review on proniosome: As a drug carrier. J. Chem. Pharm. Res.,  2021, 13(7), 1-7.

[8]
Proniosomal gel: Formulation and characterization of an antifungal drug (Butenafine Hcl) loaded proniosomes for topical delivery. Glob. J. Med. Res.,  2020, 20(5), 35-46. Available from: https://medicalresearchjournal.org/index.php/GJMR/article/download/2166/2055/

[9]
Ahmad, M.Z.; Mohammed, A.A.; Mokhtar, I.M. Technology overview and drug delivery application of proniosome. Pharm. Dev. Technol.,  2017, 22(3), 302-311.
 [http://dx.doi.org/10.3109/10837450.2015.1135344] [PMID:  26794727]

[10]
Kumar, K.; Rai, A.K. Development and evaluation of proniosomes as a promising drug carrier to improve transdermal drug delivery. Int. Res. J. Pharm.,  2011, 2(11), 71-74.

[11]
Minakshee, G.N.; Wrushali, A.P.; Shivrani, W.N.; Bhushan, R.G.; Jagdish, V.M.; Ravindra, L.B. A brief review on principle, preparation, and properties of proniosomes: A provesicular drug delivery system. World J. Pharm. Sci.,  2021, 9(5), 149-162.

[12]
Varsha, V.R.; Savitha, S.K. Proniosomes as a potential drug delivery system. J. Pharm. Sci. Res.,  2019, 11(7), 2594-2597.

[13]
Blazek-Welsh, A.I.; Rhodes, D.G. Maltodextrin-based proniosomes. AAPS PharmSci,  2001, 3(1), 1-8.
 [http://dx.doi.org/10.1208/ps030101]

[14]
Bhavani, D.G.; Laxmi, V.P. Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): A brief review of these in enhancing transdermal delivery of drug. Future J. Pharm. Sci.,  2020, 6(100), 1-18.

[15]
Mittal, S.; Chaudhary, A.; Chaudhary, A.; Kumar, A. Proniosomes: The effective and efficient drug-carrier system. Ther. Deliv.,  2020, 11(2), 125-137.
 [http://dx.doi.org/10.4155/tde-2019-0065] [PMID:  31937205]

[16]
Rajkumar, J.; Gv, R.; Sastri, KT.; Burada, S. Recent update on proniosomal gel as topical drug delivery system. Asian J. Pharm. Clin. Res.,  2019, 12(1), 54-61.
 [http://dx.doi.org/10.22159/ajpcr.2019.v12i1.28558]

[17]
Kumari, R.; Verma, K.; Verma, A.; Yadav, G.K.; Maurya, S.D. Proniosomes: A key to improved drug delivery. J. Drug Deliv. Ther.,  2014, 0(0), 56-65.
 [http://dx.doi.org/10.22270/jddt.v0i0.875]

[18]
Proniosomal gel a novel approach for drug delivery: A review. Indo Am. J. Pharm. Res.,  2017, 7(03), 7854-7860.

[19]
Jadhav, K.R.; Pawar, A.Y.; Bachhav, A.A. Proniosome: A novel non-ionic provesicules as potential drug carrier. Asian J. Pharm.,  2016, 10(3), 210-222.

[20]
Khatoon, M.; Shah, K.U.; Din, F.U.; Shah, S.U.; Rehman, A.U.; Dilawar, N.; Khan, A.N. Proniosomes derived niosomes: Recent advancements in drug delivery and targeting. Drug Deliv.,  2017, 24(2), 56-69.
 [http://dx.doi.org/10.1080/10717544.2017.1384520] [PMID:  29130758]

[21]
Kumar, G.P.; Rajeshwarrao, P. Nonionic surfactant vesicular systems for effective drug delivery-An overview. Acta Pharm. Sin. B,  2011, 1(4), 208-219.
 [http://dx.doi.org/10.1016/j.apsb.2011.09.002]

[22]
Venkatesh, D.N.; Priyanka, V.S.; Tulasi, K.; Kalyani, K.; Ali, S.A.; Jilakara, H. Proniosomes: A superior drug delivery system. Int. J. Pharm. Sci. Drug Res.,  2014, 6(3), 178-182.

[23]
Kuotsu, K.; Karim, K.M.; Mandal, A.S.; Biswas, N.; Guha, A.; Chatterjee, S.; Behera, M. Niosome: A future of targeted drug delivery systems. J. Adv. Pharm. Technol. Res.,  2010, 1(4), 374-380.
 [http://dx.doi.org/10.4103/0110-5558.76435] [PMID:  22247876]

[24]
Suryawanshi, S.S.; Patil, P.P.; Gaikwad, R.G.; Mali, S.S.; Pol, S.L. Proniosomes: Modern drug delivery system. Pharm. Res.,  2021, 4(1), 7-18.

[25]
Singla, S. Proniosomes for penetration enhancement in transdermal system. Int. J. Drug Dev. Res.,  2012, 4(2), 1-13.

[26]
Karnool, A.N. Proniosomes: Innovative vesicular drug delivery system: A review. Int. J. Pharm. Sci. Rev. Res.,  2019, 59(2), 44-51.

[27]
Mohanty, D.; Jhansi, M.; Bakshi, V.; Haque, M.A. Proniosome: A novel polymeric vesicular drug carrier. J. Glob. Trends Pharm. Sci.,  2018, 9(1), 5083-5095.

[28]
Yasam, V.R.; Jakki, S.L.; Natarajan, J.; Kuppusamy, G. A review on novel vesicular drug delivery. Proniosomes. Drug Deliv.,  2014, 21(4), 243-249.
 [http://dx.doi.org/10.3109/10717544.2013.841783] [PMID:  24128089]

[29]
Kakar, R.; Rao, R.; Goswami, A.; Nanda, S.; Saroha, K. Proniosomes: An emerging vesicular system in drug delivery and cosmetics. Der. Pharm. Lett.,  2010, 2(4), 227-239.

[30]
Sadanandan, A.; George, B.J.; Samuel, J.; Raj, P.; Thomas, N. Review on proniosomes: An innovative approach to vesicular drug delivery system. World J. Pharm. Pharm. Sci.,  2017, 6(3), 1039-1053.

[31]
Morakul, B.; Junyaprasert, V.B. Proniosomes: An effective carrier for dermal and transdermal delivery. Songklanakarin J. Sci. Technol.,  2020, 42(6), 1171-1186.

[32]
Radha, G.V.; Rani, T.S.; Sarvani, B. A review on proniosomal drug delivery system for targeted drug action. J. Basic Clin. Pharm.,  2013, 4(2), 42-48.
 [http://dx.doi.org/10.4103/0976-0105.113609] [PMID:  24808669]

[33]
Kaur, D.; Kumar, S. Niosomes: Present scenario and future aspects. J. Drug Deliv. Ther.,  2018, 8(5), 35-43.
 [http://dx.doi.org/10.22270/jddt.v8i5.1886]

[34]
Indira, U. Proniosomes as a drug carrier: A review. Int. J. Pharm. Sci. Res.,  2012, 3(12), 4617-4625.

[35]
Ajrin, M.; Anjum, F. Proniosome: A promising approach for vesicular drug delivery. J. Pharm. Sci.,  2021, 1-25.

[36]
Sankar, V.; Ruckmani, K.; Durga, S.; Jailani, S. Proniosomes as drug carriers. Pak. J. Pharm. Sci.,  2010, 23(1), 103-107.
 [PMID:  20067875]

[37]
Nimbalwar, M.G.; Gudalwar, B.R.; Panchale, W.A.; Wadekar, A.B.; Manwar, J.V.; Bakal, R.L. An overview of characterizations and applications of proniosomal drug delivery system. GSC Adv. Res. Rev.,,  2021, 7(2), 025-034.
 [http://dx.doi.org/10.30574/gscarr.2021.7.2.0095]

[38]
Sulthana, A.A.; George, B.J.; Samuel, J. Proniosomes: A future revolutionary drug delivery system. Int. J. Pharm. Chem. Biol. Sci.,  2015, 5(4), 879-882.

[39]
Song, S.; Tian, B.; Chen, F.; Zhang, W.; Pan, Y.; Zhang, Q.; Yang, X.; Pan, W. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs. Drug Dev. Ind. Pharm.,  2015, 41(1), 51-62.
 [PMID:  24111828]

[40]
Shehata, T.M.; Abdallah, M.H.; Ibrahim, M.M. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin. AAPS PharmSciTech,  2015, 16(2), 375-383.
 [http://dx.doi.org/10.1208/s12249-014-0233-5] [PMID:  25319057]

[41]
Teaima, M.H.; Yasser, M.; El-Nabarawi, M.A.; Helal, D.A. Proniosomal telmisartan tablets: Formulation, in vitro evaluation and in vivo comparative pharmacokinetic study in rabbits. Drug Des. Devel. Ther.,  2020, 14, 1319-1331.
 [http://dx.doi.org/10.2147/DDDT.S245013] [PMID:  32280201]

[42]
Hu, C.; Rhodes, D.G. Proniosomes: A novel drug carrier preparation. Int. J. Pharm.,  2000, 206(1-2), 109-122.
 [http://dx.doi.org/10.1016/S0378-5173(00)00513-5] [PMID:  11202988]

[43]
Sammour, R.M.F. Optimization of aceclofenac proniosomes by using different carriers, Part 1: Development and characterization. Pharmaceutics,  2019, 11(350), 1-19.

[44]
Nasr, M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech,  2010, 11(1), 85-89.
 [http://dx.doi.org/10.1208/s12249-009-9364-5] [PMID:  20058106]

[45]
Tamizharasi, S.; Biradar, S.; Rathi, V.; Rathi, J.C. Formulation and evaluation of maltodextrin based proniosomes loaded with indomethacin. Int. J. Pharm. Tech. Res.,  2009, 1(3), 517-523.

[46]
Sahoo, R.K.; Biswas, N.; Guha, A.; Kuotsu, K. Maltodextrin based proniosomes of nateglinide: Bioavailability assessment. Int. J. Biol. Macromol.,  2014, 69, 430-434.
 [http://dx.doi.org/10.1016/j.ijbiomac.2014.05.075] [PMID:  24909314]

[47]
Mohanty, D.; Zafar, A.; Jafar, M.; Upadhyay, A.K.; Haque, M.A.; Gupta, J.K.; Bakshi, V.; Ghoneim, M.M.; Alshehri, S.; Jahangir, M.A.; Ansari, M.J. Development, in vitro characterization and preclinical evaluation of esomeprazole-encapsulated proniosomal formulation for the enhancement of anti-ulcer activity. Molecules,  2022, 27(9), 2748.
 [http://dx.doi.org/10.3390/molecules27092748] [PMID:  35566099]

[48]
B., Solanki A.; R Parikh, J.; H Parikh, R. Preparation, optimization and characterization of ketoprofen proniosomes for transdermal delivery. IJPSN,  2009, 2(1), 413-420.
 [http://dx.doi.org/10.37285/ijpsn.2009.2.1.4]

[49]
Solanki, A.B.; Parikh, J.R.; Parikh, R.H. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS PharmSciTech,  2007, 8(4), 43.
 [http://dx.doi.org/10.1208/pt0804086] [PMID:  18181547]

[50]
Algin, Y.E.; Inal, Ö.; Tuncay, T.S.; Karavana, S.Y. Transdermal delivery of meloxicam proniosomes from hydrogels. Lat. Am. J. Pharm.,  2014, 33(3), 476-482.

[51]
Khalifa, M.K.A.; Abu El-Enin, A.S.M.; Dawaba, A.; Dawaba, H. Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation. J. Adv. Pharm. Technol. Res.,  2019, 10(1), 20-26.
 [http://dx.doi.org/10.4103/japtr.JAPTR_332_18] [PMID:  30815384]

[52]
Fang, J.Y.; Yu, S.Y.; Wu, P.C.; Huang, Y.B.; Tsai, Y.H. In vitro skin permeation of estradiol from various proniosome formulations. Int. J. Pharm.,  2001, 215(1-2), 91-99.
 [http://dx.doi.org/10.1016/S0378-5173(00)00669-4] [PMID:  11250095]

[53]
Soujanya, C.; Ravi Prakash, P. Formulation and in vivo evaluation of proniosomal gel based transdermal delivery of atorvastatin calcium. Am. J. PharmTech Res.,  2018, 8(4), 156-172.
 [http://dx.doi.org/10.46624/ajptr.2018.v8.i4.014]

[54]
Madan, J.R.; Ghuge, N.P.; Dua, K. Formulation and evaluation of proniosomes containing lornoxicam. Drug Deliv. Transl. Res.,  2016, 6(5), 511-518.
 [http://dx.doi.org/10.1007/s13346-016-0296-9] [PMID:  27255375]

[55]
Tareen, F.K.; Shah, K.U.; Ahmad, N.; Rehman, A. U.; Shah, S.U.; Ullah, N. Proniosomes as a carrier system for transdermal delivery of clozapine. Drug Dev. Ind. Pharm., 2020. [Online ahead of print]
 [http://dx.doi.org/10.1080/03639045.2020.1764020]

[56]
Sarfaraz, M.; Goel, T.; Doddayya, H. Formulation and evaluation of galantamine hydrobromide proniosome gel for Alzheimer’s disease. J. Drug Deliv. Ther.,  2020, 10(2-s), 68-74.
 [http://dx.doi.org/10.22270/jddt.v10i2-s.4027]

[57]
Fathi Azarbayjani, A.; Tan, E.H.; Chan, Y.W.; Chan, S.Y. Transdermal delivery of haloperidol by proniosomal formulations with non-ionic surfactants. Biol. Pharm. Bull.,  2009, 32(8), 1453-1458.
 [http://dx.doi.org/10.1248/bpb.32.1453] [PMID:  19652389]

[58]
Deepu, S. Formulation and evaluation of antihistaminic activity of proniosome based transdermal patches. Int. J. Res. Rev.,  2018, 5(10), 177-188.

[59]
Vora, B.; Khopade, A.J.; Jain, N.K. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J. Control. Release,  1998, 54(2), 149-165.
 [http://dx.doi.org/10.1016/S0168-3659(97)00100-4] [PMID:  9724902]

[60]
Loona, S.; Gupta, N.B.; Khan, M.U. Preparation and characterization of metformin proniosomal gel for treatment of diabetes mellitus. Int. J. Pharm. Sci. Rev. Res.,  2012, 15(2), 21.

[61]
Alsarra, I.A.; Bosela, A.A.; Ahmed, S.M.; Mahrous, G.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm.,  2005, 59(3), 485-490.
 [http://dx.doi.org/10.1016/j.ejpb.2004.09.006] [PMID:  15760729]

[62]
Sambhakar, S.; Paliwal, S.; Sharma, S.; Singh, B. Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in vitro and in vivo study. Bull. Fac. Pharm. Cairo Univ.,  2017, 55(2), 239-247.
 [http://dx.doi.org/10.1016/j.bfopcu.2017.09.003]

[63]
Thakur, R.; Anwer, M.K.; Shams, M.S.; Ali, A.; Khar, R.K.; Shakeel, F.; Taha, E.I. Proniosomal transdermal therapeutic system of losartan potassium: Development and pharmacokinetic evaluation. J. Drug Target.,  2009, 17(6), 442-449.
 [http://dx.doi.org/10.1080/10611860902963039] [PMID:  19527115]

[64]
Lee, C.K.; Zhang, S.; Venkatesan, G. Irsan; Chong, S.Y.; Wang, J.W.; Goh, W.J.; Panczyk, T.; Tay, Y.Z.; Hu, J.; Ng, W.K.; Wacker, M.G.; Toh, W.S.; Pastorin, G. Enhanced skin penetration of berberine from proniosome gel attenuates pain and inflammation in a mouse model of osteoarthritis. Biomater. Sci.,  2022, 10(7), 1752-1764.
 [http://dx.doi.org/10.1039/D1BM01733K] [PMID:  35199120]

[65]
Prajapati, S.K.; Kumar, S.; Sahu, V.K.; Prakash, G. Proniosomal gel of flurbiprofen: Formulation and evaluation. J. Drug Deliv. Ther.,  2012, 2(1), 1-5.

[66]
Khudaira, N.; Agounia, A.; Elrayess, A. Letrozole-loaded nonionic surfactant vesicles prepared via a slurry-based proniosome technology: Formulation development and characterization. J. Drug Deliv. Sci. Technol.,  2020, 58, 1-12.

[67]
Khalil, R.M.; Abdelbary, G.A.; Basha, M. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. J. Liposome Res.,  2016, 1-12.

[68]
Li, Q.; Li, Z.; Zeng, W.; Ge, S.; Lu, H.; Wu, C.; Ge, L.; Liang, D.; Xu, Y. Proniosome-derived niosomes for tacrolimus topical ocular delivery: In vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur. J. Pharm. Sci.,  2014, 62, 115-123.
 [http://dx.doi.org/10.1016/j.ejps.2014.05.020] [PMID:  24905830]

[69]
Shehata, T.M.; Ibrahim, M.M.; Elsewedy, H.S. Curcumin niosomes prepared from proniosomal gels: In vitro skin permeability, kinetic and in vivo studies. Polymers ,  2021, 13(5), 791.
 [http://dx.doi.org/10.3390/polym13050791] [PMID:  33806659]

[70]
Emad Eldeeb, A.; Salah, S.; Ghorab, M. Proniosomal gel-derived niosomes: An approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug Deliv.,  2019, 26(1), 509-521.
 [http://dx.doi.org/10.1080/10717544.2019.1609622] [PMID:  31090464]

[71]
Fouda, N.H.; Abdelrehim, R.T.; Hegazy, D.A.; Habib, B.A. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Drug Deliv.,  2018, 25(1), 1340-1349.
 [http://dx.doi.org/10.1080/10717544.2018.1477861] [PMID:  29869516]

[72]
M., Abdou E.; M Ahmed, N. Terconazole proniosomal gels: Effect of different formulation factors, physicochemical and microbiological evaluation. J. Pharm. Drug Deliv. Res.,  2016, 5(1), 1-6.
 [http://dx.doi.org/10.4172/2325-9604.1000144]

[73]
Radha, G.V.; Vinisha, V.; Rajkumar, J.; Ghosh, A. Design and evaluation of topical vaginal proniosomal formulations of tenofovir disoproxil fumarate for HIV prevention. Int. Res. J. Pharm.,  2019, 10(2), 94-102.
 [http://dx.doi.org/10.7897/2230-8407.100250]

[74]
Garg, M.; Joon, M. Novel proniosomal gel of withania somnifera.	3228/DEL/2012,, 2013.

[75]
Pre-paeonol nonionic preparation and preparation method thereof.	China Patent  CN103340823A2013.

[76]
Yadav, K.; Yadav, D.; Nanda, S.; Saroha, K. . Curcumin proniosomal/	niosomal formulation, method for its preparation and use thereof.	1288/DEL/2012A,, 2016.

[77]
Handjani, R.M.; Ribier, A.; Vanlerberghe, G.; Zabotto, A.; Griat, J. Cosmetic and pharmaceutical compositions containing niosomes and	a water-soluble polyamide, and a process for preparing these compositions.	U.S. Patent US4830857A, 1989.

[78]
Garg, M.; Joon, M.  Novel ursolic acid loaded proniosomal gel and	method of preparation thereof. 3231/DEL/2012, 2013.

[79]
Ribier, A.J.; Simonnet, T.  Process for the stabilization of vesicles of	amphiphilic lipid(s) and composition for topical application containing	the said stabilized vesicles. U.S. Patent US 6051250A, 2000.

[80]
Singh, A.; Jain, R.  Targeted vesicular Constructs for cytoprotection	and treatment of H. pylori infections. WO2000042987A8, 2000.

[81]
Laithy, H.E.; Elbary, A.A.; Tadros, M.I. A method for the preparation
of nebulisable micronized niosomes of cromolyn sodium using nonionic
surfactants. EG24388A, 
Cite As
Current Drug Delivery

A Review on Proniosomes: A Propitious Outlook to the Provesicular Drug Delivery System

Abstract

Graphical Abstract
